Drug Farm Raises $55 Mn in Series D Round

The funding round also attracted new investors, including Tukar Capital, Fuzhou Xinhe Fund, Shenzhen Luohu Donghai Chempartner Investment Fund, and Keyuan Pharma. Existing investors such as BioVeda China Fund (BVCF), YD Capital, Jiashan State VC, Detong Capital, Wedo Capital, and Biometas also joined the round.

Drug Farm will use the new funding to continue developing its clinical and preclinical drug pipeline. The investment will also help the company speed up its global clinical development programs.

In addition, the funding will support regulatory activities in key markets and help expand the company's research and development (R&D) capabilities, allowing Drug Farm to continue developing new medicines.

"The successful completion of this financing represents an important milestone in Drug Farm's mission to develop first-in-class drugs for the world. We are pleased to welcome our new investors while receiving continued support from our long-term shareholders, reflecting strong confidence in the company's scientific innovation, development strategy, and long-term vision. We believe this financing positions Drug Farm to create significant value for patients, partners, and shareholders in the years ahead,” said Dr. Tian Xu, Founder and Chairman of Drug Farm.

Dr. Henri Lichenstein, Chief Executive Officer of Drug Farm, added, "We are delighted to complete this financing and grateful for the continued confidence and support from our investors. We are proud that DF-003 is amongst the first drugs developed with AI and entering a Phase 3 trial. The investment provides additional resources to advance DF-003 through the completion of a pivotal trial in patients with ROSAH syndrome and clinical proof of concept in atherosclerotic cardiovascular disease. The funds will also be used to continue clinical development of DF-006 in patients with hepatitis B."

Dr. Tony Xu, Chief Operating Officer of Drug Farm, commented, "Powered by IDInVivo+ and MedChem5, our proprietary platforms combining genetics and artificial intelligence continues to discover and validate novel drug targets and rapidly advance multiple first-in-class candidates into the clinic. This financing will help us bring additional breakthrough therapies to patients with unmet needs in metabolic and autoimmune diseases."

Drug Farm is a private biotechnology company that develops new treatments for ROSAH syndrome, heart and kidney diseases, hepatitis B, and metabolic disorders. The company uses its IDInVivo+ platform, which combines genetics and artificial intelligence (AI), to discover and test new drug targets. It is also developing several innovative drug candidates using its MedChem5 AI platform and is moving them into clinical trials.

Read Also- BikeWo Partners with KlikAir to Explore Air Cargo Logistics Platform